87 related articles for article (PubMed ID: 31131878)
1. Histone methyltransferase SETDB1 contributes to melanoma tumorigenesis and serves as a new potential therapeutic target.
Orouji E; Federico A; Larribère L; Novak D; Lipka DB; Assenov Y; Sachindra S; Hüser L; Granados K; Gebhardt C; Plass C; Umansky V; Utikal J
Int J Cancer; 2019 Dec; 145(12):3462-3477. PubMed ID: 31131878
[TBL] [Abstract][Full Text] [Related]
2. SETDB1, an H3K9-specific methyltransferase: An attractive epigenetic target to combat cancer.
Prashanth S; Radha Maniswami R; Rajajeyabalachandran G; Jegatheesan SK
Drug Discov Today; 2024 May; 29(5):103982. PubMed ID: 38614159
[TBL] [Abstract][Full Text] [Related]
3. SETDB1: Progress and prospects in cancer treatment potential and inhibitor research.
Ma T; Xu F; Hou Y; Shu Y; Zhao Z; Zhang Y; Bai L; Feng L; Zhong L
Bioorg Chem; 2024 Apr; 145():107219. PubMed ID: 38377821
[TBL] [Abstract][Full Text] [Related]
4. SETDB1 as a cancer target: challenges and perspectives in drug design.
Hassanie H; Penteado AB; de Almeida LC; Calil RL; da Silva Emery F; Costa-Lotufo LV; Trossini GHG
RSC Med Chem; 2024 May; 15(5):1424-1451. PubMed ID: 38799223
[TBL] [Abstract][Full Text] [Related]
5. SETDB1: A perspective into immune cell function and cancer immunotherapy.
Johnson E; Salari K; Yang S
Immunology; 2023 May; 169(1):3-12. PubMed ID: 36524435
[TBL] [Abstract][Full Text] [Related]
6. The crucial role of SETDB1 in structural and functional transformation of epithelial cells during regeneration after intestinal ischemia reperfusion injury.
Ikenoue M; Choijookhuu N; Yano K; Fidya ; Takahashi N; Ishizuka T; Shirouzu S; Yamaguma Y; Kai K; Higuchi K; Sawaguchi A; Nanashima A; Hishikawa Y
Histochem Cell Biol; 2024 Apr; 161(4):325-336. PubMed ID: 38216701
[TBL] [Abstract][Full Text] [Related]
7. Hyperglycaemia aggravates periodontal inflamm-aging by promoting SETDB1-mediated LINE-1 de-repression in macrophages.
Yue Z; Nie L; Ji N; Sun Y; Zhu K; Zou H; Song X; Chen J; Wang Q
J Clin Periodontol; 2023 Dec; 50(12):1685-1696. PubMed ID: 37661095
[TBL] [Abstract][Full Text] [Related]
8. SETDB1 Inhibits p53-Mediated Apoptosis and Is Required for Formation of Pancreatic Ductal Adenocarcinomas in Mice.
Ogawa S; Fukuda A; Matsumoto Y; Hanyu Y; Sono M; Fukunaga Y; Masuda T; Araki O; Nagao M; Yoshikawa T; Goto N; Hiramatsu Y; Tsuda M; Maruno T; Nakanishi Y; Hussein MS; Tsuruyama T; Takaori K; Uemoto S; Seno H
Gastroenterology; 2020 Aug; 159(2):682-696.e13. PubMed ID: 32360551
[TBL] [Abstract][Full Text] [Related]
9. Histone Methyltransferase SETDB1: A Common Denominator of Tumorigenesis with Therapeutic Potential.
Strepkos D; Markouli M; Klonou A; Papavassiliou AG; Piperi C
Cancer Res; 2021 Feb; 81(3):525-534. PubMed ID: 33115801
[TBL] [Abstract][Full Text] [Related]
10. SETDB1 promotes the progression of colorectal cancer via epigenetically silencing p21 expression.
Cao N; Yu Y; Zhu H; Chen M; Chen P; Zhuo M; Mao Y; Li L; Zhao Q; Wu M; Ye M
Cell Death Dis; 2020 May; 11(5):351. PubMed ID: 32393761
[TBL] [Abstract][Full Text] [Related]
11. Knockout of SETDB1 gene using the CRISPR/cas-9 system increases migration and transforming activities via complex regulations of E-cadherin, β-catenin, STAT3, and Akt.
Na HH; Moon S; Kim KC
Biochem Biophys Res Commun; 2020 Dec; 533(3):486-492. PubMed ID: 32972752
[TBL] [Abstract][Full Text] [Related]
12. Histone methyltransferase SETDB1 promotes colorectal cancer proliferation through the STAT1-CCND1/CDK6 axis.
Yu L; Ye F; Li YY; Zhan YZ; Liu Y; Yan HM; Fang Y; Xie YW; Zhang FJ; Chen LH; Ding Y; Chen KL
Carcinogenesis; 2020 Jul; 41(5):678-688. PubMed ID: 31306481
[TBL] [Abstract][Full Text] [Related]
13. SETDB1 mediated histone H3 lysine 9 methylation suppresses MLL-fusion target expression and leukemic transformation.
Ropa J; Saha N; Hu H; Peterson LF; Talpaz M; Muntean AG
Haematologica; 2020 Sep; 105(9):2273-2285. PubMed ID: 33054052
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic silencing by SETDB1 suppresses tumour intrinsic immunogenicity.
Griffin GK; Wu J; Iracheta-Vellve A; Patti JC; Hsu J; Davis T; Dele-Oni D; Du PP; Halawi AG; Ishizuka JJ; Kim SY; Klaeger S; Knudsen NH; Miller BC; Nguyen TH; Olander KE; Papanastasiou M; Rachimi S; Robitschek EJ; Schneider EM; Yeary MD; Zimmer MD; Jaffe JD; Carr SA; Doench JG; Haining WN; Yates KB; Manguso RT; Bernstein BE
Nature; 2021 Jul; 595(7866):309-314. PubMed ID: 33953401
[TBL] [Abstract][Full Text] [Related]
15. Structure-Guided Discovery of a Potent and Selective Cell-Active Inhibitor of SETDB1 Tudor Domain.
Guo Y; Mao X; Xiong L; Xia A; You J; Lin G; Wu C; Huang L; Wang Y; Yang S
Angew Chem Int Ed Engl; 2021 Apr; 60(16):8760-8765. PubMed ID: 33511756
[TBL] [Abstract][Full Text] [Related]
16. SETDB1-Mediated Silencing of Retroelements.
Fukuda K; Shinkai Y
Viruses; 2020 May; 12(6):. PubMed ID: 32486217
[TBL] [Abstract][Full Text] [Related]
17. Gut stem cell necroptosis by genome instability triggers bowel inflammation.
Wang R; Li H; Wu J; Cai ZY; Li B; Ni H; Qiu X; Chen H; Liu W; Yang ZH; Liu M; Hu J; Liang Y; Lan P; Han J; Mo W
Nature; 2020 Apr; 580(7803):386-390. PubMed ID: 32296174
[TBL] [Abstract][Full Text] [Related]
18. SETDB1, a new target for immunotherapy.
Harjes U
Nat Rev Cancer; 2021 Jul; 21(7):412. PubMed ID: 34083782
[No Abstract] [Full Text] [Related]
19. SETDB1 promotes progression through upregulation of SF3B4 expression and regulates the immunity in ovarian cancer.
Yang H; Sui L; Cai C; Chu H; Diao Y
J Ovarian Res; 2024 Feb; 17(1):34. PubMed ID: 38317200
[TBL] [Abstract][Full Text] [Related]
20. Epigenome-Driven Strategies for Personalized Cancer Immunotherapy.
Rocha GIY; Gomes JEM; Leite ML; da Cunha NB; Costa FF
Cancer Manag Res; 2023; 15():1351-1367. PubMed ID: 38058537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
